Biotechnology

Gracell Biotechnologies Reports Long-term Follow-up Data on TruUCAR-enabled GC027 in Relapsed/Refractory T-ALL at the AACR 2021 Annual Meeting

SUZHOU and SHANGHAI, China, April 10, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today presented updated long...

2021-04-10 21:33 3047

Bionomics Successfully Completes A$22.9 million Equity Raise

ADELAIDE, Australia, April 9, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB:BNOEF) (Bionomics) has completed its 1 for 6 pro rata non–renounceable entitlement offer that was announced on8 March 2021 (Entitlement Offer) and concurrent placement that was announced on17 March 2021 (Concurr...

2021-04-09 18:00 3166

ImmVira Announces Preclinical and Clinical Data to Be Presented at the 2021 ASCO and AACR Annual Meeting

SHENZHEN, China, April 8, 2021 /PRNewswire/ -- ImmVira today announces that the company will be presenting its first innovative product, MVR-T3011, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting onJune 4-8 2021. Results from the first Phase 1 study of MVR-T3011 as an intr...

2021-04-08 20:47 959

Hyundai Bioscience leads in the repurposing of Niclosamide

SEOUL, South Korea, April 8, 2021 /PRNewswire/ -- A research paper by a South Korean bio tech company that demonstrated the drug repurposing of Niclosamide, an anthelmintic known to have excellent therapeutic efficacy against novel coronavirus infection (COVID-19), was published in the world-reno...

2021-04-08 17:17 874

Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-176 in EGFR-Mutant NSCLC with C797S

SEONGNAM, South Korea, April 6, 2021 /PRNewswire/ -- Bridge Biotherapeutics Inc.(288330 KQ), a clinical-stage biotech company headquartered in Seongnam, Republic of Korea, announced that the company has initiated the Phase 1/2 clinical trial assessing safety, tolerability, and anti-tumor activity...

2021-04-07 06:00 4009

MitoImmune Received FDA Clearance of IND Application for MIT-001, a Novel Anti-Inflammatory/Anti-Necrotic Therapy for Oral Mucositis in CCRT patients with Head and Neck Cancer

- MitoImmune initiates a Phase 2 trial of oral mucositis (OM) prevention in the first half of 2021 in the US and Korea, and is expanding OM treatment into hematopoietic stem cell transplantation clinical trials SEOUL, South Korea, April 6, 2021 /PRNewswire/ -- MitoIm...

2021-04-06 20:00 2170

Neurophth Announces IND Approval by the NMPA for Leber Hereditary Optic Neuropathy Gene Therapy

WUHAN and SUZHOU, China, April 1, 2021 /PRNewswire/ -- Neurophth Biotechnology Ltd., a fully-integrated genomic medicines company developing adeno-associated viral (AAV)-delivered gene therapies for the treatment of ocular diseases, recently announced the Center for Drug Evaluation (CDE) of China...

2021-04-01 20:39 4019

Gracell Biotechnologies Signs Agreement with Lonza to Manufacture Gracell's FasTCAR Product Candidates in the U.S.

SUZHOU, China and PALO ALTO, Calif., March 31, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ:GRCL)("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today ...

2021-03-31 20:45 2158

ImmuneOncia and 3D Medicines Signed Exclusive License Agreement to Develop, Manufacture and Commercialize IMC-002 in Greater China

* 3D Medicines to Lead the Manufacture, Clinical Development and Commercialization of IMC-002 for Oncology indications inGreater China * ImmuneOncia to Receive potentially up to $470.5M including $8M Upfront, and Future Development and Commercial Milestone Payments, plus Tiered Royalties on N...

2021-03-31 09:00 1307

AffaMed Therapeutics Announces Completion of over US$170 Million Series B Financing Led by Lake Bleu Capital to Further Development of Ophthalmic and Neuroscience Pipeline

SHANGHAI, March 30, 2021 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to addressing critical unmet patient need in ophthalmic, neurological and psychiatric disorders, today announced the completion of over US$170 million in Series B...

2021-03-30 19:30 719

TurtleTree Scientific and JSBiosciences enter into a strategic partnership for the development of cell culture media and contract manufacturing services

SINGAPORE, March 29, 2021 /PRNewswire/ -- JSBiosciences (hereinafter referred to as "JSBio") has just announced a partnership with TurtleTree Scientific (hereinafter referred to as "TTS"). Both parties have signed a letter of intent to collaborate in the development of cell culture media at a com...

2021-03-30 06:00 693

China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2020

BEIJING, March 29, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced its financial results for the fourth quarter and fiscal year of 2020. Fourt...

2021-03-30 04:30 2597

Tigermed Reports 2020 Annual Results With Solid Growth

HANGZHOU, China, March 29, 2021 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. (stock code: 300347.SZ / 3347.HK), a leading provider of innovative clinical research solutions for biopharmaceutical and medical device industry, reports its annual results for the year endedDecember 31, 2020 ...

2021-03-29 21:21 3031

Kintor Pharmaceutical Limited Announces 2020 Business Progress and Annual Results

SUZHOU, China, March 26, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (stock code 9939.HK, "Kintor Pharmaceutical" or the "Company"), a clinical-stage biotechnology company developing small molecule and biological therapeutics, recently announced its business highlights and financial result...

2021-03-26 20:54 5395

Bioheng Biotech Raised $80 million in Series B Financing to Advance Allogeneic Immuno-Cell Therapies

NANJING, China, March 24, 2021 /PRNewswire/ -- Bioheng Biotech Co., Ltd, a clinical-stage biotechnology companydedicated on developing novel cellular immunotherapy for cancer, today announced that it had secured $80 million in Series B Financing. The Series B was co-led by GL Ventures, the ven...

2021-03-24 22:01 18450

Transcenta Announces Appointments of Dr. Xichen Zhang as Senior Vice President of Manufacturing and Dr. Steven Yu as Senior Vice President of DMPK and Translational Science

SUZHOU, China, March 23, 2021 /PRNewswire/ -- Transcenta Holding Limited (Transcenta), aclinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced the expansion of its senior managem...

2021-03-24 08:00 609

Dr. Cheng-Chi Chao joins ChemPartner as Vice President and Head of Immunotherapy and Inflammation

SHANGHAI, March 23, 2021 /PRNewswire/ -- Shanghai ChemPartner announced today the appointment of Cheng-Chi Chao, Ph.D. as Vice President and Head of Immunotherapy and Inflammation. Dr. Chao has over 20 years of experience in drug development and extensive expertise in the fields of immune-oncolo...

2021-03-24 00:02 1257

Alphamab Oncology Reports Full Year 2020 Financial Results and Business Highlights

SUZHOU, China, March 23, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK), reported financial results for the full year ended December 31, 2020 and highlighted recent progress and upcoming milestones. Dr. Ting Xu, Chairman and CEO of Alphamab Oncology, commented, "2020 is amilestone ...

2021-03-23 23:08 3154

2020 Results Record High Despite a Challenging Year

Revenue Increased by 40.9% Y-o-Y to RMB5,612 Million Gross Profit Rose by 52.7% Y-o-Y to RMB2,533 Million Net Profit Grew by 67.5% Y-o-Y to RMB1,693 Million Record-high Gross Margin of 45.1% and Net Profit Margin of 30.2% Milestone Revenue Surged by 71.7% to US$95 Million Total Backlog up 122.0% to ...

2021-03-23 20:59 2947

VolitionRx Limited Announces Full Fiscal Year 2020 Financial Results and Business Update

* Launched first product, the Nu.Q® Vet Cancer Screening Test and recorded first revenue from sales of a commercial product * Engaged Diagnostic Oncology CRO LLC to conduct U.S. regulatory clinical trial for Non-Hodgkin's Lymphoma * Expanded research program for the use of Nu.Q® technology i...

2021-03-23 04:10 2994
12345 ... 114